hGH fragment comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-12-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
They used adult rats as the subject of their experiment and added amino acids synthesised from isotopic ammonia to their diet. When these diets were applied in nitrogen equilibrium it was found they were incorporated into tissue proteins at an intensive and rapid rate. There was also evidence of chemical transformation as heavy nitrogen was present in amino acids, which were isolated from protein, following ingestion. This chemical transformation was similar to that demonstrated in the fatty acids of his previous experiments on intermediary metabolism. The results of the experiment revealed that body proteins are in a continuous and dynamic state of synthesis and degradation. Schoenheimer and Rittenberg were responsible for discovering that body constituents were in a state of constant chemical renewal, as they were previously believed to be in a static state. Experiments on the metabolism of amino acids, fatty acids, and excretory products are used to support and demonstrate this concept of metabolic "regeneration". These molecules go through a process of replacement and interchange in the body tissue, as well as other transformations and fundamental chemical reactions. This method of isotope labelling molecules enabled Schoenheimer and his colleagues to investigate various issues in intermediary metabolism. By the late 1930s, Schoenheimer's work had contributed to the rising interest in intermediary metabolism and the isotope method.
The biosynthesis of caffeine is an example of convergent evolution among different species. Fischer's original synthesis of caffeine from 1895 began with condensation of 1,3-dimethylurea and malonic acid to form N,N'-dimethylbarbituric acid, followed by several steps of elaboration to construct the five-membered ring and add the third methyl group. Industrially, caffeine is synthesized from urea and chloroacetic acid. A range of alternative processes are also possible. Most processes for synthesizing caffeine are old, having been patented between the 1940s and the 1960s. The synthesis of caffeine is inexpensive.
=== Tissue engineering === The ability of SHG to image specific molecules can reveal the structure of a certain tissue one material at a time, and at various scales (from macro to micro) using microscopy. For instance, the collagen (type I) is specifically imaged from the extracellular matrix (ECM) of cells, or when it serves as a scaffold or conjonctive material in tissues. SHG also reveals fibroin in silk, myosin in muscles and biosynthetized cellulose. All of this imaging capability can be used to design artificials tissues, by targeting specific points of the tissue : SHG can indeed quantitatively measure some orientations, and material quantity and arrangement. Also, SHG coupled to other multiphoton techniques can serve to monitor the development of engineered tissues, when the sample is relatively thin however. Of course, they can finally be used as a quality control of the fabricated tissues.
Sources: en.wikipedia.org
Secukinumab, sold under the brand name Cosentyx among others, is a human IgG1κ monoclonal antibody used for the treatment of psoriasis, ankylosing spondylitis, psoriatic arthritis, and hidradenitis suppurativa. It binds to the protein interleukin (IL)-17A and is marketed by Novartis.
== Metabolism == 5-HTP is decarboxylated to serotonin (5-hydroxytryptamine or 5-HT) by the enzyme aromatic-L-amino-acid decarboxylase with the help of vitamin B6. This reaction occurs both in nervous tissue and in the liver. 5-HTP crosses the blood–brain barrier, while 5-HT does not. Excess 5-HTP, especially when administered with vitamin B6, is thought to be metabolized and excreted.
United States Policies targeting Muslims: Since the implementation of added security measures in the aftermath of the 2001 World Trade Centre attacks, reports of discrimination against people perceived to be Muslim by American border security officers have been prevalent in the media. The travel restrictions implemented during the Trump presidency primarily against Muslim majority countries have provoked controversy over whether such measures are a legitimate Border security measure or unethically discriminatory. Separation of families seeking asylum: In April 2018, as part of its "zero tolerance" policy, the American government ordered the separation of the children of refugees and asylum seekers from their parents. As a consequence of popular outrage, and criticism from the medical and religious communities, the policy was put on hold by an executive order signed by Trump on 20 June 2018. Under the policy, federal authorities separated children from their parents, relatives, or other adults who accompanied them in crossing the border, whether apprehended during an illegal crossing or, in numerous reported cases, legally presenting themselves for asylum. The policy involved prosecuting all adults detained at the Mexican border, imprisoning parents, and handing minors to the American Department of Health and Human Services (Spanish: Departamento de Salud y Servicios Sociales de los Estados Unidos). The federal government reported that the policy resulted in the separation of over 2300 children from their parents.
=== Kwabena Bannerman === Kwabena Bannerman (Toheeb Jimoh) is an associate trader of Ghanaian descent working for Harper’s short-only fund at Mostyn Asset Management. He and Harper are casually involved, though his laidback temperament contrasts with her intensity and single-minded focus on the business. During her controversial short of porn aggregator Siren, Harper has Kwabena draft a forceful email to investors denying redemption requests. She later recruits him to join her new fund, SternTao, but liquidates his other positions to meet a margin call from Deutsche Bank. Kwabena travels to Accra with Sweetpea to investigate Tender’s operations; using family connections, he secures a meeting that helps them uncover falsified profits and recycled revenue at a local payment processor Tender had acquired. Harper presents their findings at an investment conference, triggering a 28% drop in Tender’s stock. The Tender short ultimately nets £110 million, with Harper, Sweetpea, and Kwabena distributing £2 million each and scouting a new office for the fund. Kwabena accompanies Harper to Paris for a political fundraiser hosted by Yasmin but skips the dinner and later admits to Harper that he danced intimately with another woman that night and felt no guilt, questioning the emotional detachment in their relationship and her refusal to confront him about sleeping with Sweetpea. Harper acknowledges she avoids intimacy as self-protection, while Kwabena argues that isolating herself from those closest to her comes at too high a cost.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.